New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies

do they have a role in bridging, consolidating or conditioning transplantation treatment?

Francesca Patriarca, Luisa Giaccone, Francesco Onida, Luca Castagna, Barbara Sarina, Vittorio Montefusco, Alberto Mussetti, Nicola Mordini, Elena Maino, Raffaella Greco, Jacopo Peccatori, Moreno Festuccia, Francesco Zaja, Stefano Volpetti, Antonio Risitano, Renato Bassan, Paolo Corradini, Fabio Ciceri, Renato Fanin, Michele Baccarani & 3 others Alessandro Rambaldi, Francesca Bonifazi, Benedetto Bruno

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: Novel targeted therapies and monoclonal antibodies can be combined with allogeneic stem cell transplantation (allo-SCT) at different time-points: 1) before the transplant to reduce tumour burden, 2) as part of the conditioning in place of or in addition to conventional agents 3) after the transplant to allow long-term disease control. Areas covered: This review focuses on the current integration of new drugs with allo-SCT for the treatment of major hematological malignancies for which allo-SCT has been a widely-adopted therapy. Expert opinion: After having been used as single agent salvage treatments in relapsed patients after allo-SCT or in combination with donor lymphocyte infusions, many new drugs have also been safely employed before allo-SCT as a bridge to transplantation or after it as planned consolidation/maintenance. This era of new drugs has opened new important opportunities to ‘smartly’ combine ‘targeted drugs and cell therapies’ in new treatment paradigms that may lead to higher cure rates or longer disease control in patients with hematological malignancies.

Original languageEnglish
Pages (from-to)821-836
Number of pages16
JournalExpert Opinion on Biological Therapy
Volume17
Issue number7
DOIs
Publication statusPublished - Jul 3 2017

Fingerprint

Transplantation Conditioning
Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Hematologic Neoplasms
Stem cells
Disease control
Transplants
Pharmaceutical Preparations
Therapeutics
Salvaging
Salvage Therapy
Lymphocytes
Expert Testimony
Cell- and Tissue-Based Therapy
Tumor Burden
Consolidation
Tumors
Transplantation
Monoclonal Antibodies
Maintenance

Keywords

  • Allogeneic stem cell transplantation
  • graft-versus-tumor
  • monoclonal antibodies
  • new drugs
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies : do they have a role in bridging, consolidating or conditioning transplantation treatment? / Patriarca, Francesca; Giaccone, Luisa; Onida, Francesco; Castagna, Luca; Sarina, Barbara; Montefusco, Vittorio; Mussetti, Alberto; Mordini, Nicola; Maino, Elena; Greco, Raffaella; Peccatori, Jacopo; Festuccia, Moreno; Zaja, Francesco; Volpetti, Stefano; Risitano, Antonio; Bassan, Renato; Corradini, Paolo; Ciceri, Fabio; Fanin, Renato; Baccarani, Michele; Rambaldi, Alessandro; Bonifazi, Francesca; Bruno, Benedetto.

In: Expert Opinion on Biological Therapy, Vol. 17, No. 7, 03.07.2017, p. 821-836.

Research output: Contribution to journalReview article

Patriarca, Francesca ; Giaccone, Luisa ; Onida, Francesco ; Castagna, Luca ; Sarina, Barbara ; Montefusco, Vittorio ; Mussetti, Alberto ; Mordini, Nicola ; Maino, Elena ; Greco, Raffaella ; Peccatori, Jacopo ; Festuccia, Moreno ; Zaja, Francesco ; Volpetti, Stefano ; Risitano, Antonio ; Bassan, Renato ; Corradini, Paolo ; Ciceri, Fabio ; Fanin, Renato ; Baccarani, Michele ; Rambaldi, Alessandro ; Bonifazi, Francesca ; Bruno, Benedetto. / New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies : do they have a role in bridging, consolidating or conditioning transplantation treatment?. In: Expert Opinion on Biological Therapy. 2017 ; Vol. 17, No. 7. pp. 821-836.
@article{04aaae3583d24f109676441d2a348cfd,
title = "New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?",
abstract = "Introduction: Novel targeted therapies and monoclonal antibodies can be combined with allogeneic stem cell transplantation (allo-SCT) at different time-points: 1) before the transplant to reduce tumour burden, 2) as part of the conditioning in place of or in addition to conventional agents 3) after the transplant to allow long-term disease control. Areas covered: This review focuses on the current integration of new drugs with allo-SCT for the treatment of major hematological malignancies for which allo-SCT has been a widely-adopted therapy. Expert opinion: After having been used as single agent salvage treatments in relapsed patients after allo-SCT or in combination with donor lymphocyte infusions, many new drugs have also been safely employed before allo-SCT as a bridge to transplantation or after it as planned consolidation/maintenance. This era of new drugs has opened new important opportunities to ‘smartly’ combine ‘targeted drugs and cell therapies’ in new treatment paradigms that may lead to higher cure rates or longer disease control in patients with hematological malignancies.",
keywords = "Allogeneic stem cell transplantation, graft-versus-tumor, monoclonal antibodies, new drugs, targeted therapy",
author = "Francesca Patriarca and Luisa Giaccone and Francesco Onida and Luca Castagna and Barbara Sarina and Vittorio Montefusco and Alberto Mussetti and Nicola Mordini and Elena Maino and Raffaella Greco and Jacopo Peccatori and Moreno Festuccia and Francesco Zaja and Stefano Volpetti and Antonio Risitano and Renato Bassan and Paolo Corradini and Fabio Ciceri and Renato Fanin and Michele Baccarani and Alessandro Rambaldi and Francesca Bonifazi and Benedetto Bruno",
year = "2017",
month = "7",
day = "3",
doi = "10.1080/14712598.2017.1324567",
language = "English",
volume = "17",
pages = "821--836",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies

T2 - do they have a role in bridging, consolidating or conditioning transplantation treatment?

AU - Patriarca, Francesca

AU - Giaccone, Luisa

AU - Onida, Francesco

AU - Castagna, Luca

AU - Sarina, Barbara

AU - Montefusco, Vittorio

AU - Mussetti, Alberto

AU - Mordini, Nicola

AU - Maino, Elena

AU - Greco, Raffaella

AU - Peccatori, Jacopo

AU - Festuccia, Moreno

AU - Zaja, Francesco

AU - Volpetti, Stefano

AU - Risitano, Antonio

AU - Bassan, Renato

AU - Corradini, Paolo

AU - Ciceri, Fabio

AU - Fanin, Renato

AU - Baccarani, Michele

AU - Rambaldi, Alessandro

AU - Bonifazi, Francesca

AU - Bruno, Benedetto

PY - 2017/7/3

Y1 - 2017/7/3

N2 - Introduction: Novel targeted therapies and monoclonal antibodies can be combined with allogeneic stem cell transplantation (allo-SCT) at different time-points: 1) before the transplant to reduce tumour burden, 2) as part of the conditioning in place of or in addition to conventional agents 3) after the transplant to allow long-term disease control. Areas covered: This review focuses on the current integration of new drugs with allo-SCT for the treatment of major hematological malignancies for which allo-SCT has been a widely-adopted therapy. Expert opinion: After having been used as single agent salvage treatments in relapsed patients after allo-SCT or in combination with donor lymphocyte infusions, many new drugs have also been safely employed before allo-SCT as a bridge to transplantation or after it as planned consolidation/maintenance. This era of new drugs has opened new important opportunities to ‘smartly’ combine ‘targeted drugs and cell therapies’ in new treatment paradigms that may lead to higher cure rates or longer disease control in patients with hematological malignancies.

AB - Introduction: Novel targeted therapies and monoclonal antibodies can be combined with allogeneic stem cell transplantation (allo-SCT) at different time-points: 1) before the transplant to reduce tumour burden, 2) as part of the conditioning in place of or in addition to conventional agents 3) after the transplant to allow long-term disease control. Areas covered: This review focuses on the current integration of new drugs with allo-SCT for the treatment of major hematological malignancies for which allo-SCT has been a widely-adopted therapy. Expert opinion: After having been used as single agent salvage treatments in relapsed patients after allo-SCT or in combination with donor lymphocyte infusions, many new drugs have also been safely employed before allo-SCT as a bridge to transplantation or after it as planned consolidation/maintenance. This era of new drugs has opened new important opportunities to ‘smartly’ combine ‘targeted drugs and cell therapies’ in new treatment paradigms that may lead to higher cure rates or longer disease control in patients with hematological malignancies.

KW - Allogeneic stem cell transplantation

KW - graft-versus-tumor

KW - monoclonal antibodies

KW - new drugs

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85020271137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020271137&partnerID=8YFLogxK

U2 - 10.1080/14712598.2017.1324567

DO - 10.1080/14712598.2017.1324567

M3 - Review article

VL - 17

SP - 821

EP - 836

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 7

ER -